Androgen deprivation therapy for prostate cancer: Prescribing behaviors and preferences among urologists.

ABSTRACT:

Introduction

Several androgen deprivation therapy (ADT) medications are available for treating advanced prostate cancer with roughly equivalent oncological efficacy and tolerability. We investigated the proportion of physicians who predominantly prescribe one type of ADT drug ("mono-prescriber") and assessed characteristics associated with prescription behavior.

Methods

Ontario men aged ≥65 years who were diagnosed with advanced prostate cancer (1997-2017) and initiated ADT thereafter for ≥3 consecutive months were identified using population-level administrative data. Their first prescription for injectable ADT was linked to a physician, and urologists with ≥10 prescriptions over the study period were included in the analysis (n=282). Urologists were classified as high mono

SUBMITTER: Cheung DC 

PROVIDER: S-EPMC9565067 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature